ReviewTheranostics2026
From 2D cultures to 3D systems: evolving cancer models at the interface of functional precision medicine and theranostics.
Review in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Cancer Drug Delivery with Nanoparticles and Biomolecules: Stimuli-Responsive, Theranostic, and AI-Guided Approaches.Materials (Basel, Switzerland) · 2026Review
- Three-dimensional spheroid models in breast cancer: tumor microenvironment complexity, cancer stem cell-driven resistance, and translational model integration.Journal of translational medicine · 2026Review
- Exosome-loaded nanoradiosensitizers in radiotherapy for preventing post-irradiation tumor recurrence: mechanisms, preclinical evidence, and translational challenges.Discover nano · 2026Review
- Stem Cell-Derived Organoids for Cancer Therapy: Precision Medicine and Drug Selection.International journal of molecular sciences · 2026Review
- Designing the matrix: extracellular matrix-informed strategies for bioengineered cancer models.Frontiers in bioengineering and biotechnology · 2026Review
- Tumor Assembloids as Three-Dimensional Platforms for Modeling Drug Delivery Barriers: Construction Strategies, Applications, and Translational Challenges.Drug design, development and therapy · 2026Review
- Modeling and targeting the hostile physicochemical niche in bone metastasis: from experimental platforms to niche-directed therapy.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in patient-derived cancer models are pushing precision oncology by linking functional testing directly to therapeutic decision-making. Traditional two-dimensional (2D) cancer cell culture systems have long served as accessible tools for studying cancer biology and drug responses, but their inability to replicate the complexity of the tumor microenvironment limits their translational value. In recent years, advances in culture and imaging technologies have enabled the development of three-dimensional (3D) cancer models, such as spheroids, organoids, and patient-derived explants, that more accurately represent tumor architecture and behavior
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.